369 related articles for article (PubMed ID: 27622507)
21. Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study.
Franke MF; Ternier R; Jerome JG; Matias WR; Harris JB; Ivers LC
Lancet Glob Health; 2018 Sep; 6(9):e1028-e1035. PubMed ID: 30103980
[TBL] [Abstract][Full Text] [Related]
22. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.
Kar SK; Sah B; Patnaik B; Kim YH; Kerketta AS; Shin S; Rath SB; Ali M; Mogasale V; Khuntia HK; Bhattachan A; You YA; Puri MK; Lopez AL; Maskery B; Nair GB; Clemens JD; Wierzba TF
PLoS Negl Trop Dis; 2014 Feb; 8(2):e2629. PubMed ID: 24516675
[TBL] [Abstract][Full Text] [Related]
23. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand.
Phares CR; Date K; Travers P; Déglise C; Wongjindanon N; Ortega L; Bhuket PR
Vaccine; 2016 Jan; 34(1):128-33. PubMed ID: 26549363
[TBL] [Abstract][Full Text] [Related]
24. Feasibility, coverage and cost of oral cholera vaccination conducted by icddr,b using the existing national immunization service delivery mechanism in rural setting Keraniganj, Bangladesh.
Khan AI; Khan IA; Siddique SA; Rahman A; Islam MT; Bhuiya MAI; Saha NC; Biswas PK; Saha A; Chowdhury F; Qadri F
Hum Vaccin Immunother; 2019; 15(6):1302-1309. PubMed ID: 30261152
[No Abstract] [Full Text] [Related]
25. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
26. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial.
Qadri F; Ali M; Chowdhury F; Khan AI; Saha A; Khan IA; Begum YA; Bhuiyan TR; Chowdhury MI; Uddin MJ; Khan JAM; Chowdhury AI; Rahman A; Siddique SA; Asaduzzaman M; Akter A; Khan A; Ae You Y; Siddik AU; Saha NC; Kabir A; Riaz BK; Biswas SK; Begum F; Unicomb L; Luby SP; Cravioto A; Clemens JD
Lancet; 2015 Oct; 386(10001):1362-1371. PubMed ID: 26164097
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of a preventive mass vaccination campaign with two doses of oral cholera vaccine during a humanitarian emergency in South Sudan.
Porta MI; Lenglet A; de Weerdt S; Crestani R; Sinke R; Frawley MJ; Van Herp M; Zachariah R
Trans R Soc Trop Med Hyg; 2014 Dec; 108(12):810-5. PubMed ID: 25311798
[TBL] [Abstract][Full Text] [Related]
28. Use of oral cholera vaccine as a vaccine probe to define the geographical dimensions of person-to-person transmission of cholera.
Ali M; Kim DR; Kanungo S; Sur D; Manna B; Digilio L; Dutta S; Marks F; Bhattacharya SK; Clemens J
Int J Infect Dis; 2018 Jan; 66():90-95. PubMed ID: 29174695
[TBL] [Abstract][Full Text] [Related]
29. An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India.
Kanungo S; Desai SN; Saha J; Nandy RK; Sinha A; Kim DR; Bannerjee B; Manna B; Yang JS; Ali M; Sur D; Wierzba TF
PLoS Negl Trop Dis; 2015 May; 9(5):e0003809. PubMed ID: 26023778
[TBL] [Abstract][Full Text] [Related]
30. Oral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015.
Lam E; Al-Tamimi W; Russell SP; Butt MO; Blanton C; Musani AS; Date K
Emerg Infect Dis; 2017 Jan; 23(1):38-45. PubMed ID: 27983502
[TBL] [Abstract][Full Text] [Related]
31. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.
Ali M; Emch M; von Seidlein L; Yunus M; Sack DA; Rao M; Holmgren J; Clemens JD
Lancet; 2005 Jul 2-8; 366(9479):44-9. PubMed ID: 15993232
[TBL] [Abstract][Full Text] [Related]
32. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.
Taylor DN; Cárdenas V; Sanchez JL; Bégué RE; Gilman R; Bautista C; Perez J; Puga R; Gaillour A; Meza R; Echeverria P; Sadoff J
J Infect Dis; 2000 May; 181(5):1667-73. PubMed ID: 10823767
[TBL] [Abstract][Full Text] [Related]
33. Mass vaccination with a two-dose oral cholera vaccine in a refugee camp.
Legros D; Paquet C; Perea W; Marty I; Mugisha NK; Royer H; Neira M; Ivanoff B
Bull World Health Organ; 1999; 77(10):837-42. PubMed ID: 10593032
[TBL] [Abstract][Full Text] [Related]
34. Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016.
Ferreras E; Matapo B; Chizema-Kawesha E; Chewe O; Mzyece H; Blake A; Moonde L; Zulu G; Poncin M; Sinyange N; Kasese-Chanda N; Phiri C; Malama K; Mukonka V; Cohuet S; Uzzeni F; Ciglenecki I; Danovaro-Holliday MC; Luquero FJ; Pezzoli L
PLoS One; 2019; 14(8):e0219040. PubMed ID: 31469853
[TBL] [Abstract][Full Text] [Related]
35. Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design.
Franke MF; Jerome JG; Matias WR; Ternier R; Hilaire IJ; Harris JB; Ivers LC
Vaccine; 2017 Oct; 35(43):5819-5827. PubMed ID: 28916247
[TBL] [Abstract][Full Text] [Related]
36. The impact and cost-effectiveness of controlling cholera through the use of oral cholera vaccines in urban Bangladesh: A disease modeling and economic analysis.
Khan AI; Levin A; Chao DL; DeRoeck D; Dimitrov DT; Khan JAM; Islam MS; Ali M; Islam MT; Sarker AR; Clemens JD; Qadri F
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006652. PubMed ID: 30300420
[TBL] [Abstract][Full Text] [Related]
37. Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage.
Parker LA; Rumunu J; Jamet C; Kenyi Y; Lino RL; Wamala JF; Mpairwe AM; Muller V; Llosa AE; Uzzeni F; Luquero FJ; Ciglenecki I; Azman AS
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005652. PubMed ID: 28594891
[TBL] [Abstract][Full Text] [Related]
38. Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh.
Khan AI; Ali M; Chowdhury F; Saha A; Khan IA; Khan A; Akter A; Asaduzzaman M; Islam MT; Kabir A; You YA; Saha NC; Cravioto A; Clemens JD; Qadri F
Vaccine; 2017 Mar; 35(11):1538-1543. PubMed ID: 28196715
[TBL] [Abstract][Full Text] [Related]
39. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
[TBL] [Abstract][Full Text] [Related]
40. Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.
Kanungo S; Desai SN; Nandy RK; Bhattacharya MK; Kim DR; Sinha A; Mahapatra T; Yang JS; Lopez AL; Manna B; Bannerjee B; Ali M; Dhingra MS; Chandra AM; Clemens JD; Sur D; Wierzba TF
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003574. PubMed ID: 25764513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
